These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Engelhard VH; Bullock TN; Colella TA; Mullins DW Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498 [TBL] [Abstract][Full Text] [Related]
3. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Slingluff CL; Chianese-Bullock KA; Bullock TN; Grosh WW; Mullins DW; Nichols L; Olson W; Petroni G; Smolkin M; Engelhard VH Adv Immunol; 2006; 90():243-95. PubMed ID: 16730266 [TBL] [Abstract][Full Text] [Related]
4. Current developments in cancer vaccines and cellular immunotherapy. Ribas A; Butterfield LH; Glaspy JA; Economou JS J Clin Oncol; 2003 Jun; 21(12):2415-32. PubMed ID: 12805342 [TBL] [Abstract][Full Text] [Related]
5. Genetically modified tumour vaccines--where we are today. Nawrocki S; Mackiewicz A Cancer Treat Rev; 1999 Feb; 25(1):29-46. PubMed ID: 10212588 [TBL] [Abstract][Full Text] [Related]
6. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma. Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780 [TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810 [TBL] [Abstract][Full Text] [Related]
8. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
9. Antitumor vaccination: where we stand. Bocchia M; Bronte V; Colombo MP; De Vincentiis A; Di Nicola M; Forni G; Lanata L; Lemoli RM; Massaia M; Rondelli D; Zanon P; Tura S Haematologica; 2000 Nov; 85(11):1172-206. PubMed ID: 11074658 [TBL] [Abstract][Full Text] [Related]
10. Immunodominance across HLA polymorphism: implications for cancer immunotherapy. Kim CJ; Parkinson DR; Marincola F J Immunother; 1998 Jan; 21(1):1-16. PubMed ID: 9456431 [TBL] [Abstract][Full Text] [Related]
11. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. Hao S; Yuan J; Xiang J J Leukoc Biol; 2007 Oct; 82(4):829-38. PubMed ID: 17626150 [TBL] [Abstract][Full Text] [Related]
12. Tumor-reactive T helper lymphocytes recognize a promiscuous MAGE-A3 epitope presented by various major histocompatibility complex class II alleles. Kobayashi H; Song Y; Hoon DS; Appella E; Celis E Cancer Res; 2001 Jun; 61(12):4773-8. PubMed ID: 11406551 [TBL] [Abstract][Full Text] [Related]
13. Immune responses to human tumors: development of tumor vaccines. Platsoucas CD; Fincke JE; Pappas J; Jung WJ; Heckel M; Schwarting R; Magira E; Monos D; Freedman RS Anticancer Res; 2003; 23(3A):1969-96. PubMed ID: 12894571 [TBL] [Abstract][Full Text] [Related]
14. Differential capacity of chaperone-rich lysates in cross-presenting human endogenous and exogenous melanoma differentiation antigens. Bleifuss E; Bendz H; Sirch B; Thompson S; Brandl A; Milani V; Graner MW; Drexler I; Kuppner M; Katsanis E; Noessner E; Issels RD Int J Hyperthermia; 2008 Dec; 24(8):623-37. PubMed ID: 18608582 [TBL] [Abstract][Full Text] [Related]
15. Vaccine Trials for the Clinician: Prospects for Tumor Antigens. Osanto S Oncologist; 1997; 2(5):284-299. PubMed ID: 10388061 [TBL] [Abstract][Full Text] [Related]
16. Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments. Held G; Matsuo M; Epel M; Gnjatic S; Ritter G; Lee SY; Tai TY; Cohen CJ; Old LJ; Pfreundschuh M; Reiter Y; Hoogenboom HR; Renner C Eur J Immunol; 2004 Oct; 34(10):2919-29. PubMed ID: 15368308 [TBL] [Abstract][Full Text] [Related]
17. Molecular pathological approaches to human tumor immunology. Sato N; Hirohashi Y; Tsukahara T; Kikuchi T; Sahara H; Kamiguchi K; Ichimiya S; Tamura Y; Torigoe T Pathol Int; 2009 Apr; 59(4):205-17. PubMed ID: 19351363 [TBL] [Abstract][Full Text] [Related]
18. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028 [TBL] [Abstract][Full Text] [Related]
19. Identification of a new shared HLA-A2.1 restricted epitope from the melanoma antigen tyrosinase. Riley JP; Rosenberg SA; Parkhurst MR J Immunother; 2001; 24(3):212-20. PubMed ID: 11394498 [TBL] [Abstract][Full Text] [Related]
20. NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Zarour HM; Maillere B; Brusic V; Coval K; Williams E; Pouvelle-Moratille S; Castelli F; Land S; Bennouna J; Logan T; Kirkwood JM Cancer Res; 2002 Jan; 62(1):213-8. PubMed ID: 11782380 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]